4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Equillium, Inc. (EQ) operates in the Biotechnology industry and is headquartered in La Jolla, United States with about 14 employees. Its market capitalization is roughly $166 million. In the fiscal year ended 2025-12-31, EQ reported $0M in revenue and ($22M) in net income.
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $41M | $36M | $16M | — |
| Operating Income (EBIT) | ($24M) | ($8M) | ($14M) | ($39M) | — |
| Net Income | ($22M) | ($8M) | ($13M) | ($62M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($6M) | ($4M) | ($5M) | ($6M) | ($9M) | — |
| Net Income | ($5M) | ($4M) | ($4M) | ($6M) | ($9M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $32M | $26M | $50M | $78M | — |
| Total Liabilities | $3M | $6M | $28M | $46M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EQ viewer.
About TickerBase · Data methodology & sources